KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The clinical trial is aimed to evaluate the anti-neovascular effect of KDR2-2 suspension
eyedrop in the treatment of neovascular glaucoma. Fourty subjects would receive either 0.96
or 3.84 mg/per day/eye, in a QID fashion, ×7 days (those without complications can continue
to 28 days). The anti-neovascular effect of KDR2-2 on iris neovascularization would be
evaluated at day 1, day 7, day 14, day 28 after KDR2-2 usage.